According to Anixa Biosciences's latest financial reports the company has $23.79 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-10-31 | $23.84 M | -19.68% |
2022-10-31 | $29.68 M | -16.91% |
2021-10-31 | $35.72 M | 294.47% |
2020-10-31 | $9.05 M | 55.04% |
2019-10-31 | $5.84 M | 15.54% |
2018-10-31 | $5.05 M | -26.08% |
2017-10-31 | $6.83 M | 111.2% |
2016-10-31 | $3.23 M | -52.16% |
2015-10-31 | $6.76 M | 15.49% |
2014-10-31 | $5.86 M | 552.58% |
2013-10-31 | $0.89 M | 6.96% |
2012-10-31 | $0.83 M | -72.23% |
2011-10-31 | $3.02 M | 176.31% |
2010-10-31 | $1.09 M | -50.29% |
2009-10-31 | $2.2 M | 14.58% |
2008-10-31 | $1.92 M | 79.68% |
2007-10-31 | $1.06 M | -18.98% |
2006-10-31 | $1.31 M | 45.45% |
2005-10-31 | $0.9 M | -9.52% |
2004-10-31 | $1 M | -2.03% |
2003-10-31 | $1.02 M | 19.74% |
2002-10-31 | $0.85 M | -35.09% |
2001-10-31 | $1.31 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | $0.20 B | 774.81% | ๐บ๐ธ USA |